Moderna (MRNA) Other Working Capital Changes (2018 - 2026)

Moderna (MRNA) has 9 years of Other Working Capital Changes data on file, last reported at $5.0 million in Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 200.0% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $51.0 million, a 111.64% increase from a year earlier, with the FY2025 full-year figure at $41.0 million, up 109.34% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $5.0 million, down from $56.0 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for MRNA reached as high as $1.6 billion in Q4 2022 and fell as low as -$1.0 billion in Q4 2023.
• Historically, Other Working Capital Changes has averaged $6.5 million across 5 years, with a median of -$50.0 million in 2025.
• Across the five-year window, Other Working Capital Changes plunged 400.0% in 2022 and soared 287.5% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at $2.7 billion in 2022, then sank by 102.02% to -$54.0 million in 2023, then tumbled by 385.19% to -$262.0 million in 2024, then surged by 121.37% to $56.0 million in 2025, then slumped by 91.07% to $5.0 million in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $5.0 million in Q1 2026, $56.0 million in Q4 2025, and -$5.0 million in Q3 2025.